Brief: Adc Therapeutics Says Announced Exclusive License With Mitsubishi Tanabe Pharma Corporation To Develop And Commercialize Zynlonta® In Japan
18/01/2022 10:09
Jan 18 (Reuters) -
* ADC THERAPEUTICS ANNOUNCES EXCLUSIVE LICENSE WITH
MITSUBISHI
TANABE PHARMA CORPORATION TO DEVELOP AND COMMERCIALIZE ZYNLONTA®
(LONCASTUXIMAB TESIRINE-LPYL) IN JAPAN
Source text for Eikon: ID:nBw66rZ5pa
Further company coverage: ADCT.N
((reuters.briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview